Shoreline Biosciences Funding & Investors
Shoreline Biosciences is a biomedical company intended to establish immunotherapies for seriously ill patients. Its proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity. The company was founded in 2020 and is headquartered in La Jolla, CA, USA.
shorelinebio.comTotal Amount Raised: $183,000,000
Shoreline Biosciences Funding Rounds
Series B
$140,000,000
Series B Investors
Ally Bridge GroupBoxer CapitalIrving InvestorsBeiGeneNS InvestmentStork CapitalCormorant Asset ManagementSuperstring CapitalBiotechnology Value FundHenderson Global InvestorsCommodore CapitalKite PharmaWedbush SecuritiesEventideKingdon CapitalSeries A
$43,000,000
Series A Investors
Boxer CapitalCormorant CapitalGilead CapitalCommodore CapitalBiotechnology Value FundLogos CapitalStork CapitalHenderson Global InvestorsKite Pharma
Funding info provided by Diffbot.